Fondo Bibliografico Internacional Noviembre 2006
Cirrosis hepática y sus complicaciones.
Norfloxacin vs Ceftriaxone in the Prophylaxis of Infections
in Patients With Advanced Cirrhosis and Hemorrhage. Fernandez J, Del Arbol
LR, Gomez C, Durandez R, Serradilla R, Guarner C, Planas R, Arroyo V, Navasa
M. Gastroenterology 2006;131:1049-56.
Mayor eficacia de la ceftriaxona endovenosa en la
profilaxis de las infecciones bacterianas en pacientes cirróticos sangrantes.
Coagulation disorders and hemostasis in liver disease: pathophysiology
and critical assessment of current management. Caldwell SH, Hoffman M, Lisman
T, Macik BG, Northup PG, Reddy KR, Tripodi A, Sanyal AJ; Coagulation in Liver
Disease Group. Hepatology 2006;44:1039-46.
Revisión.
Effects of clonidine on diuretic response in ascitic patients
with cirrhosis and activation of sympathetic nervous system. Lenaerts A, Codden
T, Meunier JC, Henry JP, Ligny G. Hepatology 2006;44:844-9.
La clonidina indice una respuesta diurética
más precoz y menor requerimiento de diuréticos en los pacientes
con ascitis.
Derivation and validation of a new global method for assessing
nutritional status in patients with cirrhosis. Morgan MY, Madden AM, Soulsby
CT, Morris RW. Hepatology 2006;44:823-35.
Procedimiento simple, seguro y reproducible para
estimar el estado nutricional en la cirrosis.
Hemodynamic response-guided therapy for prevention of variceal
rebleeding: an uncontrolled pilot study. Gonzalez A, Augustin S, Perez M,
Dot J, Saperas E, Tomasello A, Segarra A, Armengol JR, Malagelada JR, Esteban
R, Guardia J, Genesca J. Hepatology 2006;44:806-12.
Interés de la evaluación de la respuesta
hemodinamica al tratamiento farmacológico de la hemorragia varicial
para prevenir el resangrado.
Impaired 11 beta-hydroxysteroid dehydrogenase contributes to
renal sodium avidity in cirrhosis: hypothesis or fact? Frey FJ. Hepatology
2006;44:795-801.
The low incidence of bacterial infections could be a protective
factor against variceal bleeding per se in hemodynamic responders to propranolol.
Senzolo M, Cholongitas E, Marelli L, Thalheimer U,
Patch D, Burroughs AK. American Journal of Gastroenterology 2006;101:2436-7.
Clinicopathological features of focal nodular hyperplasia-like
nodules in 130 cirrhotic explant livers. Libbrecht L, Cassiman D, Verslype
C, Maleux G, Van Hees D, Pirenne J, Nevens F, Roskams T. American Journal
of Gastroenterology 2006;101:2341-6.
Los nódulos similares a la hiperplasia nodular
que se observan en pacientes con cirrosis apoyan sean ocasionados por cambios
en la vascularización hepática.
Higher prevalence and severity of hepatic encephalopathy in
patients with HCV cirrhosis and diabetes mellitus: is presence of autonomic
neuropathy the missing part of the puzzle? Thuluvath PJ. American Journal
of Gastroenterology 2006;101:2244-6.
Editorial.
Efficiency and safety of bosentan in child C cirrhosis with
portopulmonary hypertension and renal insufficiency. Barth F, Gerber PJ, Reichen
J, Dufour JF, Nicod LP. European Journal of Gastroenterology and Hepatology
2006;18:1117-9.
Bosentan en la hipertensión portopulmonar. Caso clínico.
Guidelines on the management of ascites in cirrhosis. Moore
KP, Aithal GP. Gut 2006;55 Suppl 6:vi1-vi12.
Guia clínica.
A randomized controlled trial comparing ligation and sclerotherapy
as emergency endoscopic treatment added to somatostatin in acute variceal
bleeding. Villanueva C, Piqueras M, Aracil C, Gomez C, Lopez-Balaguer JM,
Gonzalez B, Gallego A, Torras X, Soriano G, Sainz S, Benito S, Balanzo J.
Journal of Hepatology 2006;45:560-7.
Superioridad de la ligadura endoscópica sobre la esclerosis en el tratamiento
urgente de la hemorragia por varices esofágicas.
The hepatopulmonary syndrome. Palma DT, Fallon MB. Journal
of Hepatolgy 2006;45:617-25.
Revisión.
